Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 16, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a specific employee retirement plan.
Material Changes
The filing details movements in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on the following dates:
- August 4, 2005: Ordinary Share ADRs held by the fund increased from 18,374,700 to 18,469,284 at an average price of $47.44.
- August 11, 2005: Ordinary Share ADRs held by the fund decreased from 18,469,284 to 18,432,773 at an average price of $47.93.
- August 12, 2005: Ordinary Share ADRs held by the fund increased from 18,432,773 to 18,475,789 at an average price of $47.90.
These changes are attributed to movements in the discretionary fund, which benefits current and former employees. Directors Dr. J.P. Garnier and Dr. T. Yamada are noted as potentially interested in these shares in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Investor Verification Checklist
- Verify the total number of ADRs held by the US Retirement Savings Plan as of August 12, 2005 (18,475,789).
- Confirm the average transaction prices for the fund movements between August 4 and August 12, 2005.
- Review the specific roles of Directors Dr. J.P. Garnier and Dr. T. Yamada regarding their potential interest in the fund.
- Check subsequent filings for any further changes in director shareholdings or fund movements.